Skip to content

Effect of chamomile ointment on incidence of phlebitis caused by amiodarone

Effect of chamomile ointment on iIncidence of phlebitis caused by intravenous amiodarone in cardiac care unit in selected Qazvin's hospitals: 2013

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014042017361N1
Enrollment
40
Registered
2014-06-02
Start date
2014-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phlebitis. Phlebitis and thrombophlebitis

Interventions

Intervention 1: This study is randomized double blind clinical trials. Drug group: The patients with ventricular or supraventricular arrhythmias that will admitted in the cardiac care unit will be
Prevention
This study is randomized double blind clinical trials. Drug group: The patients with ventricular or supraventricular arrhythmias that will admitted in the cardiac care unit will be treated with
Control group: The patients with ventricular or supraventricular arrhythmias that will admitted in the cardiac care unit will be treated with amiodarone for 24 h. Infusion of amiodarone with 150 mg o

Sponsors

Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Treated with amiodarone for 24 hours; Not allergic to chamomile ointment; Not diabetic; Age 18 to 75 years Exclusion criteria: Chamomile Ointment sensitivity expressed by patients before study entry or during the study period, based on the research team ;Scar, surgical scar or deformity that prevented IV cannula insertion of the upper limbs; Peripheral vascular disease; Use of chemotherapy medication; To prescribe oral or injectable anti-inflammatory drugs during the study period; The patient does not consent to continue to participate in the study; IV cannula exit; The drug discontinue before 24 hours; Diagnosis of diabetes after study entry; Cancer history; Patient expired; Patient discharge

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Phlebitis. Timepoint: Fisrt, Second and third 24 h. Method of measurement: Check list for phelebitis VIP (score 0-4).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Marjan Nassiri-Asl

Qazvin University of Medical Sciences

mnassiriasl@qums.ac.ir, marjannassiriaslm@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 9, 2026